Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDA

Pyramid Biosciences, Inc. announced that the US FDA has granted orphan drug designation for PBI-200, a highly brain penetrant inhibitor of the neurotrophic tyrosine receptor kinase (NTRK) currently in clinical development for the treatment of NTRK fusion-positive solid tumors.